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Abstract
Genome-wide association (GWAS) and sequencing studies are providing new insights into the genetic basis of type 2 diabetes
(T2D) and the inter-individual variation in glycemic traits, including levels of glucose, insulin, proinsulin and hemoglobin A1c
(HbA1c). At the end of 2011, established loci (P < 5 × 10−8) totaled 55 for T2D and 32 for glycemic traits. Since then, most new loci
have been detected by analyzing common [minor allele frequency (MAF)>0.05] variants in increasingly large sample sizes from
populations around the world, and in trans-ancestry studies that successfully combine data from diverse populations. Most
recently, advances in sequencing have led to the discovery of four loci for T2D or glycemic traits based on low-frequency
(0.005 <MAF≤ 0.05) variants, and additional low-frequency, potentially functional variants have been identified at GWAS loci.
Established published loci now total∼88 for T2Dand 83 forone ormore glycemic traits, andmanyadditional loci likely remain to
be discovered. Future studies will build on these successes by identifying additional loci and by determining the pathogenic
effects of the underlying variants and genes.
Introduction
Type 2 diabetes (T2D) is a common disease with substantial and
rapidly increasing global impact. While prevalence varies with
age, sex and population, the global age-standardized adult dia-
betes prevalence is >9.2%, and an estimated >347 million adults
have diabetes (1). Diabetes can be diagnosed based on the level
of blood glucose after fasting or 2 h after an oral glucose challenge
(2hGlu), or based onhemoglobinA1c (HbA1c), which provides a 3-
month average of blood glucose (2). In many individuals with
T2D, insulin resistance coexists with obesity, adverse lipid pro-
files, high blood pressure and a proinflammatory state, each like-
ly influenced by genetic and environmental factors (3).
Progression to T2D is characterized by abnormalities in pancreat-
ic islet β-cell function in the presence of insulin resistance (4), al-
though these biological processes are only partially defined.
Strong evidence for a genetic component exists for T2D risk, insu-
lin secretion and insulin action (5,6).
In the past decade, genome-wide association (GWAS) and se-
quencing studies have identified genetic loci that help explain
the inherited basis of T2D and glycemic traits. These studies
are providing insights into the genetic architecture of T2D, in-
cluding the number, frequency and effect sizes of risk variants
in populations around the world. The polygenic nature of T2D
is nowwell established, andmultiple risk variants are being iden-
tified at some loci, suggesting allelic heterogeneity. Concurrently,
increasing numbers of genes and variants have been implicated
in monogenic forms of diabetes, including maturity onset dia-
betes of the young (MODY) and neonatal diabetes (7), and at
least five genes have been implicated in both monogenic and
polygenic diabetes (8). A recent simulation study evaluated gen-
etic architectures for consistency with results from T2D genetic
studies and found that many different disease models were still
possiblewith respect to the number of loci, allele frequencies and
level of selective pressure (9). Ongoing studies should more sub-
stantially narrow the bounds on feasible architectures (9).
In this review, we describe recent genetic findings from asso-
ciation and sequencing studies for T2D and the related glycemic
traits of glucose, HbA1c, insulin and proinsulin. We generally use
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P < 5 × 10−8 as a threshold to define significant results, noting in
places where less stringent, study-wide thresholds are used.
We count distinct loci by considering multiple signals within
500 kb to be part of the same locus and consider traits with and
without adjustment for body mass index (BMI) to be the same
trait. Finally, we refer to loci by the name of a nearby gene, recog-
nizing that these genes are signposts of a locus and not necessar-
ily the genes affected by the underlying variants.
Common Variants
The development of GWAS spurred considerable progress identi-
fying commonvariants [minor allele frequency (MAF)>0.05] asso-
ciated with T2D (Table 1) and glycemic traits (Table 2). After early
candidate gene and linkage studies identified common variants
associated with T2D in PPARG, KCNJ11-ABCC8 and TCF7L2, the
first five GWAS for T2D detected six additional loci, and by early
2008, GWAS and meta-analyses had identified 15 loci for T2D
and G6PC2 as a locus for fasting glucose (10). Also in 2008, reports
of the first non-European-based GWAS for T2D established
KCNQ1 as a T2D locuswith variants common in East Asians (MAF
= 0.33) but low frequency in Europeans (MAF∼0.01) (11,12).KCNQ1
risk variants showed similar effect sizes in both populations,
demonstrating the role of allele frequency in power to detect
loci (13). In 2010, a meta-analysis of European-ancestry indivi-
duals identified a second signal of T2D-associated variants near
KCNQ1 that are not in marked linkage disequilibrium (LD) with
the initial variants (r2 < 0.05) and independent from them based
on conditional analyses (14). By the end of 2011, further GWAS
and meta-analyses in several populations had identified 55 loci
for T2D (15,16). Also by 2011, GWAS had identified 32 total loci
for one or more glycemic traits, including 17 for fasting glucose
(15,17), 2 for fasting insulin (18), 5 for 2hGlu (19), 11 for HbA1c
(20–22) and 9 for proinsulin, including 1 identified only in women
(23). Incomplete overlap of loci between T2D and glycemic traits
showed that not all effects on glucose levels in healthy indivi-
duals translate to the risk of T2D and vice versa. Based on the
overlap between traits and the biological function of nearby
genes, most identified T2D loci appeared to have a primary role
in pancreatic islet β-cell function, with far fewer impacting insu-
lin resistance.
Building on this success, an additional round of GWAS meta-
analysis made use of the Metabochip, a custom genotyping array
designed to examine ∼1000–5000 variants nominally associated
with each of 23 cardiometabolic traits/diseases and to fine-map
257 established disease- and trait-associated loci (24). This
cost-effective array allowed investigators to genotype many add-
itional samples, increasing the power ofmeta-analyses. TheDIA-
betes Genetics Replication and Meta-analysis (DIAGRAM)
Consortium meta-analyzed Metabochip data from 22 669 T2D
cases and 58 119 controls with earlier GWAS data from 12 171
T2D cases and 56 862 controls and identified 10 additional loci
(25). These loci showed further evidence of overlap with other
metabolic traits including obesity (e.g. MC4R) and lipid levels
Table 1. Eighty-eight established loci for T2D (P < 5 × 10−8)
Variant Chr Nearby gene Variant Chr Nearby gene Variant Chr Nearby gene
rs2296172 1 MACF1 rs9470794 6 ZFAND3 rs10842994 12 KLHDC5
rs17106184 1 FAF1 rs1535500 6 KCNK16 rs1531343 12 HMGA2
rs10923931 1 NOTCH2 rs2191349 7 DGKB rs7961581 12 TSPAN8, LGR5
rs340874 1 PROX1 rs864745 7 JAZF1 rs11065756 12 CCDC63
rs780094 2 GCKR rs4607517 7 GCK rs2074356 12 C12orf51
rs7578597 2 THADA rs6467136 7 GCC1, PAX4 rs7957197 12 HNF1A
rs243021 2 BCL11A rs791595 7 MIR129, LEP rs1727313 12 MPHOSPH9
rs6723108 2 TMEM163 rs972283 7 KLF14 rs9552911 13 SGCG
rs7560163 2 RBM43, RND3 rs515071 8 ANK1 rs61736969 13 TBC1D4
rs7593730 2 RBMS1 rs896854 8 TP53INP1 rs1359790 13 SPRY2
rs3923113 2 GRB14 rs13266634 8 SLC30A8 rs7403531 15 RASGRP1
rs2943641 2 IRS1 rs7041847 9 GLIS3 rs7172432 15 C2CD4A/B
rs1801282 3 PPARG rs17584499 9 PTPRD rs7178572 15 HMG20A
rs7612463 3 UBE2E2 rs10811661 9 CDKN2A/2B rs11634397 15 ZFAND6
rs831571 3 PSMD6 rs13292136 9 TLE4 rs2028299 15 AP3S2
rs4607103 3 ADAMTS9 rs2796441 9 TLE1 rs8042680 15 PRC1
rs11708067 3 ADCY5 rs11787792 9 GPSM1 rs9936385 16 FTO
rs6769511 3 IGF2BP2 rs12779790 10 CAMK1D rs7202877 16 BCAR1
rs16861329 3 ST6GAL1 rs1802295 10 VPS26A rs391300 17 SRR
rs6808574 3 LPP rs12571751 10 ZMIZ1 rs312457 17 SLC16A11/A13
rs6815464 4 MAEA rs1111875 10 HHEX, IDE rs11651052 17 HNF1B
rs1801214 4 WFS1 rs7903146 10 TCF7L2 rs8090011 18 LAMA1
rs6813195 4 TMEM154 rs10886471 10 GRK5 rs12970134 18 MC4R
rs702634 5 ARL15 rs2334499 11 DUSP8 rs12454712 18 BCL2
rs459193 5 ANKRD55 rs2237892 11 KCNQ1 rs10401969 19 CILP2
rs4457053 5 ZBED3 rs5215 11 KCNJ11 rs3786897 19 PEPD
rs35658696 5 PAM, PPIP5K2 rs1552224 11 CENTD2 rs8108269 19 GIPR
rs9502570 6 SSR1, RREB1 rs10830963 11 MTNR1B rs4812829 20 HNF4A
rs10440833 6 CDKAL1 rs11063069 12 CCND2 rs5945326 X DUSP9
rs3132524 6 POU5F1, TCF19
One representative variant and one or two genes are shown for each locus. Loci are defined as association signals located within 500 kb of each other regardless of LD.
The only locus identified first by a low-frequency variant (MAF < 0.05) is shown in bold font.
Chr, chromosome.
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(e.g. CILP2). CILP2was also identified in a contemporaneous gene-
based study (26). Network analysis of genes located near newand
established T2D signals were enriched for transcription factors,
especially those that interact with transcriptional co-activator
CREBBP, involved in chromatin remodeling (25). Analysis of direc-
tional consistency in allelic effects between stages of the meta-
analysis supported a genetic architecture consisting of many
common causal variants, most of very modest effect.
The Meta-Analyses of Glucose and Insulin-Related Traits
Consortium (MAGIC) also incorporated Metabochip data to
identify new loci (27). A meta-analysis of as many as 133 010
non-diabetic individuals identified 41new loci for glycemic traits:
20 for fasting glucose, 17 for fasting insulin and 4 for 2hGlu.
Analyses with andwithout adjustment for BMI allowed addition-
al loci to be detected, especially for fasting insulin. Of 53 total gly-
cemic loci, 34 showed at least nominal association (false
discovery rate q < 0.05) with other metabolic traits, including in-
sulin loci for T2D, lipid traits and waist–hip ratio, consistent
with insulin resistance and potentially implicating pleiotropic ef-
fects. Of 36 fasting glucose loci, 22 showed at least nominal asso-
ciation with T2D (q < 0.05), but many other glucose loci had no
apparent effect on T2D.
Genetic studies performed since 2012 have identified many
additional T2D loci based on risk alleles common in one popula-
tion but less common in others. Studies in African Americans
identified RND3-RBM43 (28), HLA-B and INS-IGF2 (29). Studies in
Table 2. Eighty-three established loci for one or more glycemic traits (P < 5 × 10−8)
Variant Chr Nearby gene Traits Variant Chr Nearby gene Traits
rs6684514 1 TMEM79 H rs7034200 9 GLIS3 G
rs2779116 1 SPTA1 H rs10811661 9 CDKN2A/2B G
rs340874 1 PROX1 G rs16913693 9 IKBKAP G
rs2820436 1 LYPLAL1 I rs306549 9 DDX31 P
rs1371614 2 DPYSL5 G rs651007 9 ABO G
rs780094 2 GCKR G, I rs3829109 9 DNLZ G
rs895636 2 SIX3, SIX2 G rs16926246 10 HK1 H
rs1530559 2 YSK4 I rs10885122 10 ADRA2A G
rs10195252 2 GRB14 I rs7903146 10 TCF7L2 G, I, P
rs560887 2 G6PC2 G, H rs7077836 10 TCERG1L I
rs733331 2 PDK1 G rs11605924 11 CRY2 G
rs2943645 2 IRS1 I rs7944584 11 MADD G, P
rs17036328 3 PPARG I rs1483121 11 OR4S1 G
rs11715915 3 AMT G rs174550 11 FADS1 G
rs11708067 3 ADCY5 G rs11603334 11 ARAP1 G, P
rs11920090 3 SLC2A2 G rs10830963 11 MTNR1B G, H
rs7651090 3 IGF2BP2 G rs2657879 12 GLS2 G
rs3822072 4 FAM13A I rs150781447 12 TBC1D30 P
rs9884482 4 TET2 I rs35767 12 IGF1 I
rs6822892 4 PDGFC I rs12229654 12 MYL2 G
rs17046216 4 SC4MOL I rs2074356 12 C12orf51 G
rs4865796 5 ARL15 I rs11066453 12 OAS1 G
rs459193 5 ANKRD55 I rs10747083 12 P2RX2 G
rs7708285 5 ZBED3 G rs11619319 13 PDX1 G
rs6235 5 PCSK1 G, P rs576674 13 KL G
rs1019503 5 ERAP2 G rs61736969 13 TBC1D4 G, I
rs35658696 5 PAM, PPIP5K2 I rs7998202 13 ATP11A H
rs17762454 6 RREB1 G rs3783347 14 WARS G
rs9368222 6 CDKAL1 G, H rs4502156 15 C2CD4A/B G, P
rs1800562 6 HFE H rs1549318 15 LARP6 P
rs6912327 6 UHRF1BP1 I rs2018860 15 IGF1R G
rs10305492 6 GLP1R G rs1421085 16 FTO I
rs2745353 6 RSPO3 I rs9933309 16 CYBA H
rs9399137 6 HBS1L, MYB H rs4790333 17 SGSM2 P
rs2191349 7 TMEM195 G rs1046896 17 FN3K H
rs4607517 7 GCK G, H rs11667918 19 MYO9B H
rs6943153 7 GRB10 G rs731839 19 PEPD I
rs1167800 7 HIP1 I rs10423928 19 GIPR G
rs983309 8 PPP1R3B G, I rs6113722 20 FOXA2 G
rs4737009 8 ANK1 H rs6072275 20 TOP1 G
rs11558471 8 SLC30A8 G, P rs855791 22 TMPRSS6 H
rs3824420 9 KANK1 G, P
One representative variant, one or two genes and one-letter abbreviations for the glycemic traits analyzed in the discovery association studies are shown for each locus.
Not all traits are shown. Loci are defined as association signals located within 500 kb of each other regardless of LD. Loci identified first by a low-frequency variant
(approximate MAF <0.05) are shown in bold font.
Chr, chromosome; G, glucose (fasting, 1hGlu, 2hGlu or these traits adjusted for BMI); I, insulin (fasting or fasting and adjusted for BMI) or insulinogenic index; H,
hemoglobin A1c; P, proinsulin (fasting and adjusted for BMI and insulin).
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South Asians identified TMEM163 (30) and SGCG (31). One locus,
SLC16A11-SLC16A13, was simultaneously identified in Japanese
and Mexican Americans (32,33), and studies in East Asians iden-
tified ANK1 (34), GRK5 and RASGRP1 (35), LEP and GPSM1 (32), and
CCDC63 and C12orf51 (36). A study of individuals from Greenland
identified TBC1D4 (37), and a sequencing-based study of Danes
with follow-up in other Europeans identified MACF1 (38). Finally,
the largest GWAS to date in American Indians identified DNER at
near genome-wide significance (P = 6.6 × 10−8) (39). Three of these
studies imputed GWAS data using the 1000 Genomes Project se-
quence-based reference panels, providing better genome cover-
age (29,32,33,40). Taken together, these studies highlight the
value of diverse populations, including founder and historically
isolated populations, to detect risk loci.
Novel glycemic trait loci have also been identified since 2012
in selected populations or by analyzing additional glycemic
traits. Studies in African Americans identified SC4MOL and
TCERG1L for fasting insulin (41), and the TBC1D4 locus identified
in Greenland was also strongly associated with 2hGlu and 2hIns
(37). Studies in East Asians identified C12orf51, KANK1, IGF1R and
PDK1-RAPGEF4 for fasting glucose; MYL2, C12orf51 and OAS1 for
1-2hGlu and HBS1L-MYB, CYBA and MYO9B for HbA1c (42–44).
Additional loci were identified for measures of islet β-cell func-
tion derived from glycemic traits: insulinogenic index (HNF1A)
and disposition index (ABO) (45). ABO encodes a well-known blood
group, was previously implicated in blood cell and lipid traits and
was subsequently reported as a locus for fasting insulin (46).
MAGIC also used association evidence from fasting traits and
dynamic tests of insulin secretion after glucose challenge to
characterize T2D loci (47). Clusters of loci appear to have primary
effects on insulin sensitivity (PPARG, KLF14, IRS1, GCKR), reduced
insulin secretion and fasting hyperglycemia (MTNR1B, GCK), in-
sulin processing (ARAP1), and insulin processing and secretion
without a detectable change in fasting glucose levels (TCF7L2,
SLC30A8, HHEX-IDE, CDKAL1, CDKN2A); another 20 loci evaluated
did not clearly fit any of these clusters (47). Future studies are
needed to better understand pathogenetic effects on physiology.
Meta-analyses across populations provide further oppor-
tunities to detect loci with shared risk alleles. Meta-analysis
of 17 418 T2D cases and 70 298 controls from European, Afri-
can-American, Hispanic-Latino, and Asian studies using a
gene-based CardioChip array was first to identify the BCL2
locus for T2D (26). A recent genome-wide trans-ancestry
meta-analysis of 26 488 T2D cases and 83 964 controls from
European, East Asian, South Asian and Mexican ancestry,
with follow-up in an additional 21 491 T2D cases and 55 647
controls of European ancestry, identified seven new T2D loci
(48). The trans-ancestry part of this latter study was performed
using variants imputed based on genotype data from the Inter-
national HapMap Project (49), and follow-up was limited to var-
iants available in Metabochip-typed datasets, suggesting that
future trans-ancestry meta-analyses incorporating data im-
puted to denser reference panels will identify additional loci.
Another strategy that identified loci for T2D and glycemic
traits considered the relationship between these traits and BMI.
Analysis of T2D in lean (BMI < 25 kg/m2) compared with obese
(BMI ≥ 30 kg/m2) individuals identified LAMA1 as a T2D locus
with larger effect in lean (odds ratio 1.13, 95% confidence interval
1.09–1.18) than obese (odds ratio 1.03, 95% confidence interval
1.00–1.06) cases (50). Another study of fasting glucose and insulin
applied a joint meta-analysis approach to simultaneously test
both a main genetic effect, adjusted for BMI, and potential inter-
action between each genetic variant and BMI (51). Many of the
significant associations in that study also were detected in the
concurrent MAGICMetabochip study; additional loci detected in-
cluded a fasting glucose locus at DPYSL5 and a locus >1 Mb from
MADD, yet still inmoderate (r2∼0.2) LDwith aMADD signal. A full
understanding of the genetic architecture of T2D and glycemic
traitswill involve teasing apart genetic contributions that depend
on correlated traits.
Low-Frequency and Rare Variants
Technological advances and lower costs of high-throughput se-
quencing have driven new discoveries of low-frequency (0.005 <
MAF ≤ 0.05) and rare (MAF ≤ 0.005) variants associated with T2D
or related glycemic traits. Novel signals include both new loci
and new low-frequency variants at established loci. Approaches
to discover these variants include exome or genome sequencing,
genotyping arrays and imputation reference panels that include
variants identified by sequencing, and gene-based tests that ag-
gregate variants. The threshold of significance used in current
studies varies; while the large number of rare variants suggests
the need for thresholds more stringent than P < 5 × 10−8, some
studies use study-wide significance based on the number of var-
iants analyzed or the number of genes analyzed in gene-based
tests.
Four new loci for T2D or glycemic traits were recently identi-
fied using low-frequency or rare variants (45,46,52,53) (Tables 1
and 2). The first exome array-based study to identify novel loci re-
ported low-frequency missense variants (MAF = 0.020–0.029)
associatedwith proinsulin levels at TBC1D30 (Arg279Cys, P = 5.5 ×
10−11) and KANK1 (Arg667His, P = 1.3 × 10−8) (Fig. 1), and border-
line low-frequency missense variants (MAF = 0.053) in the PAM
(Asp563Gly, P = 1.9 × 10−8) and PPIP5K2 (Ser1228Gly, P = 2.3 × 10−8)
genes, located ∼100 kb apart, associated with insulinogenic
Figure 1. A low-frequency Finnish missense variant and a common non-coding
East Asian variant may tag the same signal at KANK1. The KANK1 locus was
originally identified in an exome array study in Finns by a low-frequency
missense variant associated with fasting proinsulin (rs3824420, red arrow) (45).
Many additional non-coding variants analyzed subsequently, shown here, are
also associated with proinsulin in Finns (LD coloring, 1000 Genomes EUR). Also
at KANK1, an East Asian GWAS meta-analysis detected a common variant
(rs10815355) associated with fasting glucose (43). The East Asian signal (r2 > 0.8,
purple dotted rectangle) does not include the missense variant (43).
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index (45). A whole-genome sequencing and imputation study
showed that the missense variants in PAM and PPIP5K2 were
also associated with T2D (P = 3.9 × 10−10) (52). That study reported
an additional rare (MAF = 0.006)missense variant in PAMwith in-
dependent evidence of T2D association (Ser539Trp, P = 1.7 × 10−5),
implicating PAM as the more likely T2D gene at this locus. Most
recently, an exome array-based study identifiedmissense variant
GLP1RAla316Thr (MAF = 0.014) associatedwith fasting glucose le-
vels (P = 3.4 × 10−12) (46). A concurrent exome array study using
partly overlapping samples supports this association (P = 4.6 ×
10−7) (53). The latter study also identified a novel fasting insulin
locus at study-wide significance (URB2 Glu594Val, MAF = 0.001,
P = 3.1 × 10−7) (53). These association signals represent the first
of potentially many novel loci that will be identified based on
low-frequency variants.
Recent studies have also identified low-frequency variants
associated with T2D at established GWAS loci but distinct from
the common GWAS variants based on LD and conditional ana-
lysis. At CCND2, Steinthorsdottir described an intronic variant
(rs76895963, MAF = 0.015) that reduces T2D risk (P = 5.0 × 10−21)
and is correlated with increased CCND2 expression (54). Two
studies identified low-frequency variants in MODY genes asso-
ciated with T2D in the general population, frameshift variant
PDX1 Gly218Alafs*12 associated with the increased risk of T2D
at study-wide significance (MAF = 0.002, P = 7.3 × 10−7) (52) and
HNF1A Glu508Lys associated with reduced T2D risk (MAF = 0.021,
P = 2.4 × 10−9) (55).
Low-frequency variants distinct from GWAS loci have also
been described for glycemic traits. An exome array study in
Finns identified variants in SGSM2 (Val996Ile, MAF = 0.014) and
MADD (Arg776X,MAF = 0.037) associatedwith proinsulin and dis-
tinct from the GWAS variants (45). At the MADD locus, another
study identified a rare (MAF = 0.00068) variant associated with
fasting glucose within NR1H3 intron 2 that shows evidence of a
functional regulatory effect (56). Also, an exome array study of
Europeans identified missense variant G6PC2 His177Tyr (MAF =
0.008) associated with fasting glucose (P = 3.1 × 10−8) (53). Evi-
dence of allelic heterogeneity may help identify the underlying
genes and facilitate biological studies.
A productive approach to analyzing exonic variants is to
aggregate them into gene-based tests. Aggregating SLC30A8
variants identified by sequencing or genotyping ∼150 000 indivi-
duals, Flannick showed that carriers of 12 rare protein-truncating
variants had a 3-fold reduced risk of T2D (P = 1.7 × 10−6) (54).
Another study used gene-based tests of up to 15 variants as
evidence that three coding variants in G6PC2 (Val219Leu,
His177Tyr, Tyr207Ser) are associated with fasting glucose levels
independent of each other and the non-coding GWAS signal.
Wessel also reported a significant gene-based association at
G6PC2 (P = 6.8 × 10−6) (46). Gene-based tests are most powerful
when they combine only variants that have a functional effect,
without neutral variants, as elegantly demonstrated by two stud-
ies that tested the function of multiple missense variants in
MTNR1B or PPARG using cell-based assays (57,58). Compared
with aggregating all knownmissense variants in those genes, ag-
gregating only the variants that showed functional effects
strengthened evidence of T2D association (57,58).
Other Aspects of Genetic Architecture
The genetic architecture of T2D and glycemic traits is also influ-
enced by parent-of-origin effects and sex differences. An Iceland-
ic study was first to report that variants located near KCNQ1,
MOB2 and KLF14 showed stronger evidence of association when
maternally inherited than when paternally inherited (59). The
parent-of-origin effect at these three variants and others was
subsequently confirmed in Pima Indians (60). A GWASmeta-ana-
lysis for proinsulin reported a locus at DDX31 more significant in
women (P = 2.0 × 10−8) than men (P = 0.17)(23), and the DIAGRAM
consortium reported the CCND2 signal was more significant in
men (Pmen = 1.1 × 10
−9, Pwomen P = 0.036; Phet = 0.013) and the GIPR
signal wasmore significant in women (Pwomen = 2.2 × 10
−7, Pmen =
0.0037; Phet = 0.057); the sex difference at CCND2 was not repli-
cated in a study of individuals from Iceland, Denmark and Iran
(52). Among low-frequency variants, loci with stronger evidence
observed in one sex include a missense variant in PAM
(rs35658696) associated with T2D (Pmen = 5.2 × 10
−10, Pwomen =
0.0044; Phet = 0.033) (52); the association of this variant with insu-
linogenic index was observed in an all-male study (45). More ex-
tensive study of these and other influences may improve
understanding of the mechanisms by which variants in or near
these genes influence traits or confer susceptibility to disease.
Conclusion and Future Directions
Together, published loci identified at P < 5 × 10−8 total ∼88 for T2D
and 83 for one or more of glucose, HbA1c, insulin and proinsulin.
Counts are slightly more or less depending on whether variants
hundreds of kilobases apart represent the same or different loci.
CombiningT2Dand these glycemic traits,∼137 loci have been iden-
tified. Of these, only four were identified based on low-frequency
variants, and none based on rare variants alone. Loci were discov-
ered in many different populations and typically share direction of
effect across populations when they are observed.
New loci will continue to be observed as sample sizes increase
and asmore variants are analyzed. Imputation panels built using
larger numbers of individuals, such as the >39million variants in
∼65 000 haplotypes from the first release of the Haplotype Refer-
ence Consortium (www.haplotype-reference-consortium.org/
last accessed on 6 July 2015), will improve the genome coverage
of meta-analyses and help identify signals with previously un-
tested variants. New loci will be identified with lower-frequency
variants based on large numbers of sequenced exomes from the
T2D-GENES, PROMIS, CHARGE, UK10K and other consortia. Add-
itional loci will be detected based on gene-based tests, especially
as annotation for both coding and non-coding regions improves.
Results of these studies will more narrowly define the feasible
models of genetic architecture for T2D and glycemic traits. Ultim-
ately, the greatest value from these studies will come with the
discovery of the underlying genes and biological mechanisms re-
sponsible for disease.
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